AIHTA - Publications - Search - Browse by Type
Number of items: 8.

AIHTA Appraisal Board Author Group, HTA Austria (2026): Tisotumab vedotin (TIVDAK®) for the treatment of adult patients with recurrent or metastatic cervical cancer. Decision Support Document for the Austrian Appraisal Board 008.

AIHTA Appraisal Board Author Group, HTA Austria (2026): Teplizumab (TEIZEILD®) for stage 2 type 1 diabetes. Decision Support Document for the Austrian Appraisal Board 007.

AIHTA Appraisal Board Author Group, HTA Austria (2025): Dorocubicel + unexpanded CD34– cells (Zemcelpro®) for the treatment of haematological malignancies in adults. Decision Support Document for the Austrian Appraisal Board 006.

AIHTA Appraisal Board Author Group, HTA Austria (2025): Obecabtagene autoleucel (AUCATZYL®) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. Decision Support Document for the Austrian Appraisal Board 005.

AIHTA Appraisal Board Author Group, HTA Austria (2025): Lifileucel (AMTAGVI®) for previously treated unresectable or metastatic melanoma. Decision Support Document for the Austrian Appraisal Board 004.

Colicchia, A. and Fabian, D. and Grabenhofer, L. and Geiger-Gritsch, S. and Grössmann-Waniek, N. and Malikova, E. and Rothschedl, E. and Sehic, O. and Wild, C. and Wolf, S. and Zechmeister-Koss, I. (2025): Teprotumumab (TEPEZZA®) for moderate-to-severe thyroid eye disease. Decision Support Document for the Austrian Appraisal Board 003.

Colicchia, A. and Fabian, D. and Grabenhofer, L. and Grössmann-Waniek, N. and Malíková, E. and Rothschedl, E. and Sehic, O. and Wild, C. and Wolf, S. and Zechmeister-Koss, I. (2025): Fidanacogene elaparvovec (BEQVEZ®) for the treatment of moderately severe to severe haemophilia B. Decision Support Document for the Austrian Appraisal Board 002.

Grössmann-Waniek, N. and Wild, C. and Malíková, E. and Wolf, S. and Fabian, D. and Sehic, O. and Zechmeister-Koss, I. (2025): Exagamglogene autotemcel (Exa-cel, Casgevy®) for the treatment of beta-thalassaemia and severe sickle cell disease. Decision Support Document for the Austrian Appraisal Board 001.

This list was generated on Fri Jun 26 10:00:16 2026 CEST.